MARKET

CGEN

CGEN

Compugen
NASDAQ
2.705
-0.025
-0.92%
After Hours: 2.701 -0.004 -0.15% 17:20 05/20 EDT
OPEN
2.730
PREV CLOSE
2.730
HIGH
2.780
LOW
2.700
VOLUME
265.47K
TURNOVER
--
52 WEEK HIGH
3.235
52 WEEK LOW
1.295
MARKET CAP
255.77M
P/E (TTM)
7.18
1D
5D
1M
3M
1Y
5Y
1D
Compugen Earnings Call Highlights Trials, Cash Runway
TipRanks · 1d ago
Analysts’ Top Healthcare Picks: Compugen (CGEN), TriSalus Life Sciences (TLSI)
TipRanks · 1d ago
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program
Seeking Alpha · 1d ago
Compugen: Advancing Clinical Pipeline and AstraZeneca Partnership Underpin Buy Rating with Unchanged $4 Price Target
TipRanks · 1d ago
Closing Bell Movers: Agilysys jumps 14% on Q4 beat and strong guide
TipRanks · 2d ago
Compugen files $400M mixed securities shelf
TipRanks · 2d ago
Compugen Q1 Net Loss Expands; On Track For Interim Analysis Of COM701 MAIA-ovarian Trial ;Stock Up
NASDAQ · 2d ago
Compugen Posts Q1 2026 Results, Cites Strong Cash Runway and Pipeline Advances
TipRanks · 2d ago
More
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Webull offers Compugen Ltd (USA) stock information, including NASDAQ: CGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEN stock methods without spending real money on the virtual paper trading platform.